Top 10 Things You Need to Know in the New PBC Landscape

Program Overview

Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease characterized by the destruction of intrahepatic bile ducts that, if left untreated, can lead to liver failure and ultimately, the need for liver transplantation. This Top 10 program in PBC has been designed to provide a concise and easily navigated platform that will help raise awareness of disease in order to support its early identification and the timely implementation of effective therapy. Our expert, Dr. Gideon M. Hirschfield will provide his insights on the top 10 most common questions regarding the evolving PBC landscape. Additionally, Ms. Carol Roberts, a PBC patient, transplant recipient, and current President of the PBCers Organization—an online and in-person PBC support group—will provide her lived experience and the invaluable perspectives of the many patients affected by PBC.

Target Audience

The educational design of this activity addresses the needs of gastroenterology and hepatology specialist physicians, nurse practitioners (NPs), and physician associates (PAs) who are involved in managing patients with PBC.

Educational Objectives

After completing this activity, the participant should be better able to:

• Identify signs and symptom manifestations of PBC in order to employ evidence-based diagnostic criteria and noninvasive assessment strategies early within the disease course
• Outline data on the safety, efficacy, and placement of novel peroxisome proliferator-activated receptor (PPAR) agonist therapies for the treatment of PBC
• Adopt timely monitoring schedules to assess disease symptoms, treatment response, and need to escalate pharmacotherapy

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Recognition Statement

• Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
• For ABIM MOC points, your information will be shared with the ABIM through Integritas' Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
• By sharing your Diplomate Board ID # and DOB, you are giving Integritas Communications permission to use this information/data to report your participation to these Boards via the Program and Activity Reporting System (PARS).

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty has the following relevant financial relationships with ineligible companies:

Gideon Hirschfield, MB BChir, FRCP, PhD: Consulting Fees: Advanz Pharma Corp., Cymabay Therapeutics, Inc., Falk Foundation e. V., Gilead Sciences, Inc., GSK, Intercept Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Mirum Pharmaceuticals Inc., Pliant Therapeutics, Inc.

The planners and managers have no relevant financial relationships with ineligible companies:

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.